Bright Minds Biosciences (DRUG) Net Income towards Common Stockholders (2023 - 2024)
Bright Minds Biosciences (DRUG) posted Net Income towards Common Stockholders of $35513.3 for Q4 2024, down 78.87% on a QoQ basis from $168091.4 in Q2 2024, and up 102.87% year-over-year from $17505.4 in Q1 2024.
Bright Minds Biosciences (DRUG) Net Income towards Common Stockholders (2023 - 2024) Analysis & Trends
Bright Minds Biosciences' Net Income towards Common Stockholders history runs 2 years deep, the most recent figure standing at $35513.3 for Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Bright Minds Biosciences | 683.37 Mn | 683.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 35,513.28 |
| Jun 30, 2024 | 168,091.41 |
| Dec 31, 2023 | -1.24 Mn |
| Jun 30, 2023 | -1.09 Mn |